Latest Biotech News

ADC specialist Tubulis expanded its Series C to $401 million with an additional $40 million injection two weeks after closing the original tranche. The Munich‑based company said the funds will...

Evommune filed to go public, targeting roughly $150 million in an IPO priced between $15 and $17 per share to advance its two phase‑2 clinical assets. The proceeds will support EVO756, an oral...

Google announced that a large foundation model in its Gemma family—Cell2Sentence‑Scale—proposed and validated a novel drug combination for cancer, marking an AI‑driven discovery advance. The firm...

Novo Nordisk submitted an unsolicited offer valuing Metsera at roughly $9 billion, prompting Metsera’s board to deem the proposal “superior” to Pfizer’s earlier agreement. The two-step bid...

The U.S. Food and Drug Administration placed a clinical hold on two late-stage Phase 3 trials of Intellia Therapeutics’ CRISPR candidate nexiguran ziclumeran (nex‑z) after a Grade 4 liver adverse...

The FDA proposed draft guidance to remove the routine requirement for comparative clinical efficacy trials in many biosimilar applications, aiming to shorten development timelines and lower costs...

Eli Lilly reported a blowout third quarter with $17.6 billion in revenue, driven by tirzepatide sales that topped $10.1 billion across diabetes and obesity brands (Mounjaro and Zepbound)....

Sequencing giant Illumina reported $1.08 billion in third‑quarter revenue, effectively flat year‑over‑year, and modestly raised its full‑year 2025 revenue and EPS guidance. CEO Jacob Thaysen...

4D Molecular Therapeutics agreed to sell Asia‑Pacific commercialization rights for its retinal gene therapy 4D‑150 to Otsuka Pharmaceutical, securing $85 million upfront and potential milestone...

Nanobiotix secured $71 million in non‑dilutive financing from HealthCare Royalty to support its cash runway into early 2028 and advance a Johnson & Johnson‑partnered radiotherapy‑activated...

Google unveiled an advanced foundation model in the Cell2Sentence‑Scale family that proposed and (per company reports) experimentally validated a novel drug combination for cancer. Built on the...

Guardant Health announced commercial entry into the multi‑cancer detection (MCD) market with its Shield test and reported Q3 earnings that lifted investor sentiment. The company said use of Shield...

Thermo Fisher Scientific agreed to acquire Clario for $8.9 billion in cash (plus an additional earnout), folding the clinical‑trial data and patient‑centric platform into its portfolio. The...

Novo Nordisk made an unsolicited, up-to‑$9 billion two-step offer for obesity biotech Metsera, topping Pfizer’s earlier agreement and triggering a four-business-day window for Pfizer to match or...

The US Food and Drug Administration unveiled draft guidance proposing to eliminate routine Phase III comparative efficacy studies for many biosimilar submissions, aiming to lower development cost...

The FDA placed a formal clinical hold on two late‑stage Intellia trials testing its CRISPR therapy nexiguran ziclumeran after a participant experienced a grade‑4 liver injury with elevated...

4D Molecular Therapeutics sold Asia‑Pacific rights to its retinal gene therapy 4D‑150 to Otsuka Pharmaceutical for $85 million up front plus potential cost‑sharing and up to $336 million in...

Nanobiotix secured a $71 million non‑dilutive loan from HealthCare Royalty to fund operations through early 2028, pledging a portion of future royalties and milestone payments tied to its...

BridgeBio reported that encaleret met primary and key secondary endpoints in a global Phase III study for autosomal dominant hypocalcemia type 1 (ADH1), with 76% of treated patients achieving...

Illumina reported $1.08 billion in Q3 revenues—roughly flat year‑over‑year—and beat adjusted EPS expectations with $1.34, citing strength in clinical sequencing outside China. The company raised...